Letter by Koh Regarding Article, “Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)”
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
To the Editor:
Kosiborod et al1 reported that treatment with sodium-glucose cotransporter-2 inhibitor versus other glucose-lowering drugs was associated with a lower risk of hospitalization for heart failure and death, suggesting that the benefits seen with empagliflozin in a randomized trial may be a class effect applicable to a broad population of patients with type 2 diabetes mellitus in real-world practice.
People with type 2 diabetes mellitus want anti–diabetes mellitus treatments to lower both glucose levels and risk of cardiovascular disease, heart failure, and all-cause mortality. Therefore, many studies have been performed to estimate …